Portal de Periódicos da CAPES

Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial

2021; Springer Nature; Volume: 46; Issue: 5 Linguagem: Inglês

10.1038/s41386-020-00948-6

1740-634X

Maria Antonietta Nettis, Giulia Lombardo, Caitlin Hastings, Zuzanna Zajkowska, Nicole Mariani, Naghmeh Nikkheslat, Courtney Worrell, Daniela Enache, Anna McLaughlin, Melisa Kose, Luca Sforzini, Anna Bogdanova, Anthony J. Cleare, Allan H. Young, Carmine M. Pariante, Valeria Mondelli,

Vitamin D Research Studies

This study aimed to investigate the role of baseline levels of peripheral inflammation when testing the efficacy of antidepressant augmentation with minocycline in patients with treatment-resistant depression. We conducted a 4-week, placebo-controlled, randomised clinical trial of minocycline (200 mg/day) added to antidepressant treatment in 39 patients selected for elevated levels of serum C-reactive protein (CRP ≥ 1 mg/L), n = 18 randomised to minocycline (M) and n = 21 to placebo (P). The main outcome was the change in Hamilton Depression Rating Scale (HAM-D-17) score from baseline to week 4, expressed both as mean and as full or partial response, in the overall sample and after further stratification for baseline CRP≥3 mg/L. Secondary outcomes included changes in other clinical and inflammatory measures. Changes in HAM-D-17 scores and the proportion of partial responders did not differ between study arms. After stratification for CRP levels <3 mg/L (CRP